The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database
The clinically observed AEs, along with potential new AE signals associated with empagliflozin were identified based on the FAERS database, which could provide valuable evidence for clinical monitoring, risk identification, and further safety studies of identification.
Authors
- Huiping Hu (ORCID: https://orcid.org/0000-0002-4647-950X)
- Zhiwen Fu (ORCID: https://orcid.org/0000-0002-0635-1368)
- Kaiping Wang (ORCID: https://orcid.org/0000-0001-6572-3435)
- Zi Huang (ORCID: https://orcid.org/0000-0002-9738-4949)
- Maochang Liu (ORCID: https://orcid.org/0000-0002-2371-4060)
- Shijun Li (ORCID: https://orcid.org/0000-0002-3622-9435)
Institutions
- Union Hospital (HK)
- Beijing University of Chinese Medicine (CN)
- Wuhan Children's Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1186/s40360-025-00861-y
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- National Natural Science Foundation of China